1. MRI sequences are important for evaluating the stages of an ischemic stroke, including the hyperacute, acute, and chronic stages.
2. Diffusion-weighted imaging shows cytotoxic edema in the hyperacute phase, while perfusion imaging can identify potentially reversible penumbra tissue.
3. In the acute phase from 12 hours to 3 days, T1-weighted imaging with contrast shows intravascular and meningeal enhancement and parenchymal changes.
4. In the subacute phase from 3 days to 6 weeks, contrast enhancement decreases while edema and mass effect resolve over time.
1. MRI sequences are important for evaluating the stages of an ischemic stroke, including the hyperacute, acute, and chronic stages.
2. Diffusion-weighted imaging shows cytotoxic edema in the hyperacute phase, while perfusion imaging can identify potentially reversible penumbra tissue.
3. In the acute phase from 12 hours to 3 days, T1-weighted imaging with contrast shows intravascular and meningeal enhancement and parenchymal changes.
4. In the subacute phase from 3 days to 6 weeks, contrast enhancement decreases while edema and mass effect resolve over time.
1. MRI sequences are important for evaluating the stages of an ischemic stroke, including the hyperacute, acute, and chronic stages.
2. Diffusion-weighted imaging shows cytotoxic edema in the hyperacute phase, while perfusion imaging can identify potentially reversible penumbra tissue.
3. In the acute phase from 12 hours to 3 days, T1-weighted imaging with contrast shows intravascular and meningeal enhancement and parenchymal changes.
4. In the subacute phase from 3 days to 6 weeks, contrast enhancement decreases while edema and mass effect resolve over time.
1. MRI sequences are important for evaluating the stages of an ischemic stroke, including the hyperacute, acute, and chronic stages.
2. Diffusion-weighted imaging shows cytotoxic edema in the hyperacute phase, while perfusion imaging can identify potentially reversible penumbra tissue.
3. In the acute phase from 12 hours to 3 days, T1-weighted imaging with contrast shows intravascular and meningeal enhancement and parenchymal changes.
4. In the subacute phase from 3 days to 6 weeks, contrast enhancement decreases while edema and mass effect resolve over time.
- HS T2, FLAIR (la 4-6h) edem citotoxic (s cenusie), apoi vasogenic (s alba) - T1 ef de masa disparitia santurilor intergirale - stergerea cisternei insulare - comprimarea VL - disparitia hsemn intravasc normal det de flx a rapid (ocluzie/viteza mica) - + civ -> enhancement intravasal, evidentiaza perfuzia de lux de la perif infarctului - DWI HS (prabusirea pompei Na/K, edem citotoxic, limit difuziei H2O); ADC hS = nucleul infarctului (lez irevers) - PWI (+civ) evaluarea perf in 1-2 min -> hperf arata lez reversibile (penumbra) + irevers PWI DWI = mismatch -> indic de tromboliza
STD ACUT, DE NECROZA ISCH (12h 3 zile)
- HS T2, hS T1, margini flu, terit a - efect de masa (max in z 3-6) - T1+civ -> enhancement intravazal meningeal parenchim giriform (alter BHE) - transf hemoragica T2 hS (dezoxiHb)
STD SUBAC, DE RESORBTIE (z3 6s)
4-7 z creste priza de civ masiv, pseudotum dispare cea intravasc si mening ef de masa moderat, in scadere transf hemoragica T1 HS metHb petesiala, cuprinzand pred s cenusie, cu aspect giriform la niv cortexului si petesial patat in nc bazali 1-6 s scaderea edemului si a ef de masa persista civ parench moderat, giriform transf hemoragica HS T1 infarct hS T1, HS T2, limita neta
STD CR, ENCEFALOMALACIE (>6s)
- cav porencefalica (encefalomalacica) semnal asem cu LCR, marginita de glioza (HS FLAIR) - fara ef de masa, ci ef retractil - fara priza de civ - transf hemoragica hS T2 (hemosiderina) - atrofie + degen walleriana retrograda a caii py
IRM CEREBRAL IN AVC HEMORAGIC
Std hemoragiei Tip de Hb T1 T2 Edem Supraacut (1- OxiHb ic hS (plasma) HS (plasma) - 6h) (Diamagnetica) Ac (6h-4z) DezoxiHb ic Izo-hS hS (>=1T) + (Paramagnetica) izoS (< 1T) Subac (5z-s) Precoce MetHb ic HS hS + Tardiv MetHb ec HS HS + (puternic paramagnetica)
Cronic (s-ani) Central cavitate hS HS
Periferic hemosiderina hS - izoS hS
DIVERSE:
Arteriopatia Moya-Moya idiopatica
- la tineri - AIT, AVC I, hemoragie cerebrala, epi - stenoza lent progresiva + ocluzia vaselor cercului Willis -> colaterale anormal de fragile
Sdr Ac antiPL - avorturi spontane recurente - tromboze v - trombocitopenie